Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 25, 2023
Data Byte
Aggressive cuts part of Novartis’ focus on higher-potential pipeline
The pharma’s latest quarterly update revealed a pruning of 10% of its pipeline, including several early-stage cancer programs
BioCentury | Feb 23, 2023
Deals
Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
BioCentury | Aug 6, 2020
Product Development
Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red
BioCentury | Jul 11, 2019
Targets & Mechanisms
The tumor stroma rises as the newest source of immuno-oncology targets
Why companies are turning to the tumor stroma to overcome resistance to checkpoint inhibitors
BioCentury | May 12, 2016
Distillery Therapeutics
Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)
Items per page:
1 - 9 of 9